What do systematic reviews say?

Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO

• Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations 2018 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported
• Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations 2018 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO

• Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations 2018 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported
• Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations 2018 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO

It is very uncertain whether risk‐reducing salpingo‐oophorectomy (RRSO) changes breast cancer mortality: ≤ 50 years compared with no RRSO (very low certainty).

• Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations 2018 · Cochrane Headline outcomes only
  HR 0.78 [0.55, 1.09]
  3 studies · 4566 participants
  Very low
• Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations 2018 · Cochrane Headline outcomes only
  HR 0.49 [0.08, 2.9]
  2 studies · 444 participants
  Very low

Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO

It is very uncertain whether risk‐reducing salpingo‐oophorectomy (RRSO) changes breast cancer mortality: > 50 years compared with no RRSO (very low certainty).

• Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations 2018 · Cochrane Headline outcomes only
  HR 1.27 [0.67, 2.38]
  3 studies · 4566 participants
  Very low
• Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations 2018 · Cochrane Headline outcomes only
  HR 1.36 [0.68, 2.75]
  2 studies · 444 participants
  Very low

Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO

It is very uncertain whether risk‐reducing salpingo‐oophorectomy (RRSO) changes breast cancer mortality: BRCA1 or BRCA compared with no RRSO (very low certainty).

• Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations 2018 · Cochrane Headline outcomes only
  HR 0.58 [0.39, 0.88]
  7 studies · 7198 participants
  Very low

Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO

• Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 200 participants
  Very low

Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO

• Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 200 participants
  Very low

Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO according to BRCA mutation status

It is very uncertain whether risk‐reducing salpingo‐oophorectomy (RRSO) changes overall survival: BRCA1 only compared with no RRSO according to BRCA mutation status (very low certainty).

• Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations 2018 · Cochrane Headline outcomes only
  HR 0.3 [0.17, 0.52]
  3 studies · 2548 participants
  Very low

Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO according to BRCA mutation status

It is very uncertain whether risk‐reducing salpingo‐oophorectomy (RRSO) changes overall survival: BRCA2 only compared with no RRSO according to BRCA mutation status (very low certainty).

• Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations 2018 · Cochrane Headline outcomes only
  HR 0.44 [0.23, 0.85]
  2 studies · 2122 participants
  Very low